116 related articles for article (PubMed ID: 28119123)
21. Role of (18) F-FDOPA PET/CT imaging in endocrinology.
Santhanam P; Taïeb D
Clin Endocrinol (Oxf); 2014 Dec; 81(6):789-98. PubMed ID: 25056984
[TBL] [Abstract][Full Text] [Related]
22. A technique for standardized central analysis of 6-(18)F-fluoro-L-DOPA PET data from a multicenter study.
Whone AL; Bailey DL; Remy P; Pavese N; Brooks DJ
J Nucl Med; 2004 Jul; 45(7):1135-45. PubMed ID: 15235059
[TBL] [Abstract][Full Text] [Related]
23. Current status of 18F-DOPA PET imaging in the detection of brain tumor recurrence.
Calabria F; Cascini GL
Hell J Nucl Med; 2015; 18(2):152-6. PubMed ID: 26187216
[TBL] [Abstract][Full Text] [Related]
24. Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-phenyl-alanine and 11C-5-hydroxy-tryptophan positron emission tomography.
Koopmans KP; Neels OC; Kema IP; Elsinga PH; Sluiter WJ; Vanghillewe K; Brouwers AH; Jager PL; de Vries EG
J Clin Oncol; 2008 Mar; 26(9):1489-95. PubMed ID: 18349401
[TBL] [Abstract][Full Text] [Related]
25. (18)F-DOPA Positron Emission Tomography in Medulloblastoma: 2 Case Reports.
Cicone F; Clerico A; Minniti G; Paiano M; Carideo L; Scaringi C; Langen KJ; Scopinaro F
World Neurosurg; 2016 Sep; 93():490.e7-490.e11. PubMed ID: 27354292
[TBL] [Abstract][Full Text] [Related]
26. Comparison of [18F]FDOPA, [18F]FMT and [18F]FECNT for imaging dopaminergic neurotransmission in mice.
Honer M; Hengerer B; Blagoev M; Hintermann S; Waldmeier P; Schubiger PA; Ametamey SM
Nucl Med Biol; 2006 Jul; 33(5):607-14. PubMed ID: 16843835
[TBL] [Abstract][Full Text] [Related]
27. ¹⁸F-DOPA PET/computed tomography imaging.
Chondrogiannis S; Marzola MC; Rubello D
PET Clin; 2014 Jul; 9(3):307-21. PubMed ID: 25030394
[TBL] [Abstract][Full Text] [Related]
28. Imaging of advanced neuroendocrine tumors with (18)F-FDOPA PET.
Becherer A; Szabó M; Karanikas G; Wunderbaldinger P; Angelberger P; Raderer M; Kurtaran A; Dudczak R; Kletter K
J Nucl Med; 2004 Jul; 45(7):1161-7. PubMed ID: 15235062
[TBL] [Abstract][Full Text] [Related]
29. (18)F-DOPA PET/CT and MRI: description of 12 histologically-verified pheochromocytomas.
Magnaldi S; Mayerhoefer ME; Khameneh A; Schuetz M; Javor D; Mitterhauser M; Dudczak R; Hacker M; Karanikas G
Anticancer Res; 2014 Feb; 34(2):791-5. PubMed ID: 24511014
[TBL] [Abstract][Full Text] [Related]
30. 18F-DOPA PET/CT biodistribution consideration in 107 consecutive patients with neuroendocrine tumours.
Chondrogiannis S; Grassetto G; Marzola MC; Rampin L; Massaro A; Bellan E; Ferretti A; Mazza A; Al-Nahhas A; Rubello D
Nucl Med Commun; 2012 Feb; 33(2):179-84. PubMed ID: 22083098
[TBL] [Abstract][Full Text] [Related]
31. Characterization of hyperinsulinism in infancy assessed with PET and 18F-fluoro-L-DOPA.
Ribeiro MJ; De Lonlay P; Delzescaux T; Boddaert N; Jaubert F; Bourgeois S; Dollé F; Nihoul-Fékété C; Syrota A; Brunelle F
J Nucl Med; 2005 Apr; 46(4):560-6. PubMed ID: 15809476
[TBL] [Abstract][Full Text] [Related]
32. PET imaging of medullary thyroid carcinoma in MEN2A transgenic mice using 6-[(18)F]F-L-DOPA.
Pestourie C; Thézé B; Kuhnast B; Le Helleix S; Gombert K; Dollé F; Tavitian B; Ducongé F
Eur J Nucl Med Mol Imaging; 2010 Jan; 37(1):58-66. PubMed ID: 19655139
[TBL] [Abstract][Full Text] [Related]
33. Hyperechogenicity of the substantia nigra in healthy controls is related to MRI changes and to neuronal loss as determined by F-Dopa PET.
Behnke S; Schroeder U; Dillmann U; Buchholz HG; Schreckenberger M; Fuss G; Reith W; Berg D; Krick CM
Neuroimage; 2009 Oct; 47(4):1237-43. PubMed ID: 19497378
[TBL] [Abstract][Full Text] [Related]
34. 18F-DOPA PET and PET/CT.
Nanni C; Fanti S; Rubello D
J Nucl Med; 2007 Oct; 48(10):1577-9. PubMed ID: 17909255
[No Abstract] [Full Text] [Related]
35. Impact of 3,4-dihydroxy-6-18F-fluoro-L-phenylalanine PET/CT on managing patients with brain tumors: the referring physician's perspective.
Walter F; Cloughesy T; Walter MA; Lai A; Nghiemphu P; Wagle N; Fueger B; Satyamurthy N; Phelps ME; Czernin J
J Nucl Med; 2012 Mar; 53(3):393-8. PubMed ID: 22323780
[TBL] [Abstract][Full Text] [Related]
36. 18F-DOPA and other radiopharmaceuticals for imaging unknown primary neuroendocrine tumors.
Schillaci O
J Nucl Med; 2014 Mar; 55(3):357-9. PubMed ID: 24396031
[No Abstract] [Full Text] [Related]
37. Whole body 18fluoro-L-dopa PET-CT: a useful tool for location and surgical guidance in primary carcinoid tumours.
Arbizu J; Rodriguez-Fraile M; Dominguez-Prado I; Garrastachu P; Rotellar F; Sangro B; Richter JA
Eur J Nucl Med Mol Imaging; 2008 Aug; 35(8):1577. PubMed ID: 18566820
[No Abstract] [Full Text] [Related]
38. Staging of carcinoid tumours with 18F-DOPA PET: a prospective, diagnostic accuracy study.
Koopmans KP; de Vries EG; Kema IP; Elsinga PH; Neels OC; Sluiter WJ; van der Horst-Schrivers AN; Jager PL
Lancet Oncol; 2006 Sep; 7(9):728-34. PubMed ID: 16945767
[TBL] [Abstract][Full Text] [Related]
39. Correlation of 6-18F-fluoro-L-dopa PET uptake with proliferation and tumor grade in newly diagnosed and recurrent gliomas.
Fueger BJ; Czernin J; Cloughesy T; Silverman DH; Geist CL; Walter MA; Schiepers C; Nghiemphu P; Lai A; Phelps ME; Chen W
J Nucl Med; 2010 Oct; 51(10):1532-8. PubMed ID: 20847166
[TBL] [Abstract][Full Text] [Related]
40. Monosymptomatic resting tremor and Parkinson's disease: a multitracer positron emission tomographic study.
Ghaemi M; Raethjen J; Hilker R; Rudolf J; Sobesky J; Deuschl G; Heiss WD
Mov Disord; 2002 Jul; 17(4):782-8. PubMed ID: 12210876
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
